Bond.az White LogoBond.az Black Logo
→
EN ▾
AZENRU
Russian Army Captures Two Villages in UkraineEvercore ISI Reiterates Amphenol Outperform $180 TargetModric to retire after 2026 World CupOkta price target raised to $110 by CantorOppenheimer Cuts Deere Price Target on Brazil WeaknessCongratulations to President Ilham AliyevAI chip stocks rise, Iran talks uncertainNewegg director sells $589,390 in stockWhy was school No. 122 in Zira closed?ECB Flags Hedge Fund Bond Leverage RisksRussian Army Captures Two Villages in UkraineEvercore ISI Reiterates Amphenol Outperform $180 TargetModric to retire after 2026 World CupOkta price target raised to $110 by CantorOppenheimer Cuts Deere Price Target on Brazil WeaknessCongratulations to President Ilham AliyevAI chip stocks rise, Iran talks uncertainNewegg director sells $589,390 in stockWhy was school No. 122 in Zira closed?ECB Flags Hedge Fund Bond Leverage Risks
Personalize
Bond.az White LogoBond.az Black Logo
AZENRU

#central-precocious-puberty

Latest news and interesting information about central-precocious-puberty.

FP-001 42 mg Clinical Trial Completed
Today / 09:02
|
855

FP-001 42 mg Clinical Trial Completed

Foresee Pharmaceuticals completes Phase 3 trial for FP-001 42 mg for precocious puberty. FDA submission planned for 2026. CAMCEVI 21mg approved in Europe.

COMPANY →
0
...